Bioprocessing of New Medicines (Business and Management)

About this course

Bioprocessing of new medicines sits at the frontier of pharmaceutical development, focusing on the biological and engineering processes by which modern therapies, including vaccines, monoclonal antibodies, cell and gene therapies, and other biological medicines, are designed, produced, and scaled up for manufacture. It is a highly applied science that bridges biology, chemistry, and engineering, and it is one of the fastest-growing areas in healthcare. This variant of the programme at UCL includes a significant component in business and management, recognising that the pharmaceutical and biotech industries require people who can navigate commercial strategy, regulatory environments, and organisational leadership as well as understanding the science. At University College London, this three-year degree develops your scientific grounding in the biological principles underlying drug develo

Where its graduates go

The 5 largest scored destinations, covering 60% of graduates; the headline also reflects the subject baseline.

• 72 / 100Information Technology Professionals · 5% of graduatescards →
• 60 / 100Business, Research and Administrative Professionals · 15% of graduatescards →
• 55 / 100Administrative occupations · 10% of graduatescards →
• 52 / 100Finance Professionals · 15% of graduatescards →
• 48 / 100Business and public service associate professionals · 15% of graduatescards →

The tabs above carry the rest: modules and satisfaction (The Course), where you'd live and what it costs (Student Life), the full pay story (Pay & Outcomes), and easier ways into the same subject (Alternatives).